What question did this study set out to answer?

Evaluate the risk of new or recurrent malignancy in IBD patients with a history of cancer treated with biologics or small molecules.

January 23, 2026Journal of Crohn s and Colitis

P0716Safety of biologic and small molecule therapies in IBD patients with previous cancer: risk of recurrence or new neoplasia

View Full Paper

Ask AI

Bookmark

Evaluate the risk of new or recurrent malignancy in IBD patients with a history of cancer treated with biologics or small molecules.
Real-world, multicentre Spanish study using the ENEIDA registry.
Included adults with IBD and a history of extracolonic cancer.
Compared incidence rates of cancer by drug exposure using Poisson regression models.
961 patients included, mean age at cancer diagnosis was 52 years.
155 patients developed cancer recurrence or new cancer during follow-up.
Adjusted incidence rate ratios showed lower risks for vedolizumab, ustekinumab, and small molecules compared to anti-TNF therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Findings demonstrate low cancer risk in IBD patients with previous cancer treated with biologics or small molecules, suggesting general safety for therapy.

Cite This Study

Varela et al. (2026) studied this question.

synapsesocial.com/papers/69730ed4c8125b09b0d1eacd https://doi.org/10.1093/ecco-jcc/jjaf231.897

View Full Paper

Ask AI

Bookmark

Implication

Findings demonstrate low cancer risk in IBD patients with previous cancer treated with biologics or small molecules, suggesting general safety for therapy.

P0716Safety of biologic and small molecule therapies in IBD patients with previous cancer: risk of recurrence or new neoplasia

Key Points

Discussion

Implication

Cite This Study

P0716Safety of biologic and small molecule therapies in IBD patients with previous cancer: risk of recurrence or new neoplasia

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading